NCT05087264 is a EARLY_PHASE1 clinical trial of Indocyanine green in Cervical Carcinoma, sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University.

Who is sponsoring NCT05087264?

NCT05087264 is sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University.

What drugs are being tested in NCT05087264?

Interventions in NCT05087264: Indocyanine green.

What condition does NCT05087264 study?

NCT05087264 studies Cervical Carcinoma.

Is NCT05087264 still recruiting?

NCT05087264 is currently status unknown. Last updated 18 March 2022.

Last reviewed 2022-03-18 · How we verify

NCT05087264

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Indocyanine Green Displaying Pelvic Nerve in Radical Operation of Cervical Cancer

Status unknown EARLY_PHASE1 Last updated 18 March 2022

What this trial tests

EARLY_PHASE1 trial testing Indocyanine green in Cervical Carcinoma in 86 participants. Status unknown.

Timeline

10 March 2022

Primary endpoint
16 October 2025

16 October 2025

Quick facts

Lead sponsor	Fifth Affiliated Hospital, Sun Yat-Sen University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	86
Start date	10 March 2022
Primary completion	16 October 2025
Estimated completion	16 October 2025
Sites	1 location across China

Drugs / interventions tested

Indocyanine green (INDOCYANINE GREEN) — full drug profile →

Conditions studied

Cervical Carcinoma — all drugs for Cervical Carcinoma →

Sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 18 to 75, female only, with Cervical Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Indocyanine green was injected intravenously into patients with cervical cancer before operation. The nerve development was observed by infrared imaging system during operation, which was used as the basis for nerve preserving operation of type C cervical cancer. The recovery of bladder function was observed.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Intraoperative fluorescence redefining neurosurgical precision.
Regmi M, Li Y, Wang Y, Liu W, et al · · 2025 · cited 7× · PMID 38913424 · DOI 10.1097/js9.0000000000001847
NIR-II fluorescence imaging with ICG improves intraoperative visualization of pelvic autonomic nerves.
Qu Q, Nie H, Hou S, Guo X, et al · · 2026 · PMID 41692588 · DOI 10.1002/ctm2.70602

Verify or expand the search:

Other trials of Indocyanine green

Trials testing the same drug.

NCT06164392 — Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography · Phase 4 · withdrawn
NCT06169735 — Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation · Phase 4 · recruiting
NCT06322862 — FLuorescence Guided Assessment of Mesenteric Ischemia in Emergency Surgery · NA · recruiting
NCT06227338 — ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study · NA · recruiting
NCT06939946 — Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI) · Phase 1 · terminated

Other recruiting trials for Cervical Carcinoma

Currently open trials in the same condition.

NCT07407647 — Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Fifth Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

NCT06079931 — The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia · Phase 2 · unknown
NCT06525025 — Building a Traditional Chinese Medicine Clinical Diagnosis and Treatment Database · not yet recruiting
NCT06060782 — Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine · Phase 1 · recruiting
NCT06220552 — The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma · Phase 2 · recruiting
NCT06147947 — Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of CSPH in Patients With cACLD · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05087264 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fifth Affiliated Hospital, Sun Yat-Sen University
Last refreshed: 18 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05087264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing